PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 15, 2003Journal of Clinical Investigation461 citationsOpen Access

Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human

KHKobra HaghighiFKFotis KolokathisLPLuke Pater

Key Result

A naturally occurring loss-of-function human phospholamban mutation (PLN-L39stop) caused lethal dilated cardiomyopathy in homozygous individuals, contrasting with the benign phenotype observed in mice.

Study Design

Type

Observational (n=106)

Multicenter

No

Structured PICO

Does a loss-of-function mutation in the phospholamban (PLN) gene cause dilated cardiomyopathy in humans?

P
Population
76 patients with dilated cardiomyopathy (average ejection fraction 22.9%) and 30 normal subjects recruited from the Onassis Cardiac Surgery Center, along with family pedigrees of affected individuals.
I
Intervention
Naturally occurring T116G point mutation (L39stop) in the phospholamban (PLN) gene (heterozygous and homozygous).
C
Comparator
Wild-type PLN (normal subjects) and PLN-null mouse models.
O
Outcome
Development of dilated cardiomyopathy, heart failure, and need for cardiac transplantation, along with in vitro assessment of SR Ca2+ transport and myocyte mechanics.hard clinical

A naturally occurring loss-of-function mutation in human phospholamban causes lethal dilated cardiomyopathy, revealing a critical species difference compared to the benign phenotype observed in PLN-null mice.

Limitations

  • Cannot rule out that a highly unstable/rapidly degraded and inactive form of PLN may initiate human dilated cardiomyopathy.
  • Environmental and unidentified genetic influences likely contribute to the variable expression of the clinical phenotype.
  • Cannot rule out the possibility that a highly unstable/rapidly degraded and inactive form of PLN, associated with the PLN-L39stop mutation, may initiate human dilated cardiomyopathy.

Abstract

In human disease and experimental animal models, depressed Ca(2+) handling in failing cardiomyocytes is widely attributed to impaired sarcoplasmic reticulum (SR) function. In mice, disruption of the PLN gene encoding phospholamban (PLN) or expression of dominant-negative PLN mutants enhances SR and cardiac function, but effects of PLN mutations in humans are unknown. Here, a T116G point mutation, substituting a termination codon for Leu-39 (L39stop), was identified in two families with hereditary heart failure. The heterozygous individuals exhibited hypertrophy without diminished contractile performance. Strikingly, both individuals homozygous for L39stop developed dilated cardiomyopathy and heart failure, requiring cardiac transplantation at ages 16 and 27. An over 50% reduction in PLN mRNA and no detectable PLN protein were noted in one explanted heart. The expression of recombinant PLN-L39stop in human embryonic kidney (HEK) 293 cells and adult rat cardiomyocytes showed no PLN inhibition of SR Ca(2+)-ATPase and the virtual absence of stable PLN expression; where PLN was expressed, it was misrouted to the cytosol or plasma membrane. These findings describe a naturally-occurring loss-of-function human PLN mutation (PLN null). In contrast to reported benefits of PLN ablation in mouse heart failure, humans lacking PLN develop lethal dilated cardiomyopathy.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Haghighi et al. (2003) conducted an observational in Dilated cardiomyopathy (n=106). PLN-L39stop mutation vs. Wild-type PLN was evaluated on Development of dilated cardiomyopathy and heart failure. A naturally occurring loss-of-function human phospholamban mutation (PLN-L39stop) caused lethal dilated cardiomyopathy in homozygous individuals, contrasting with the benign phenotype observed in mice.

synapsesocial.com/papers/6a07b3e744ff8ad339f69a67https://doi.org/10.1172/jci17892
Ask AI
Helpful
Bookmark
Share
View Full Paper